Akero Therapeutics (AKRO): Company Cash Volume

Graphic logo of akerotx.com (AKRO)

The current cash position demonstrates the financial stability of Akero Therapeutics (AKRO). The company relies on a team of top biochemists whose motivation is secured through stock option programs. This potential is bolstered by the development of efruxifermin to combat NASH. Meanwhile, the patent protection of new molecules promises years of excess profits from liver therapy. The 0.72 metric determines the status of the issuer's liquidity parameter.

Company Cash Volume: Akero Therapeutics, Inc. (AKRO) for 07/04/2022 - 12/20/2025

Financial and market metric breakdowns for Akero Therapeutics, Inc. (AKRO)

- stock value and consensus price forecast:
Analysis of all company metrics:Akero Therapeutics AKRO
Signature product of Akero

To assess the financial stability of Akero Therapeutics (AKRO), it is critical to monitor the liquidity reserve that ensures seamless interaction with contract manufacturers within its asset-light model. By analyzing the volume of highly liquid cash assets, an investor determines the company's ability to fund operating activities without external borrowing, noting that excessive reserve accumulation may reduce the overall return on equity during a shift in the market cycle.